Friday, October 09, 2020 2:10:56 PM
9:00 AM ET 10/1/20 | BusinessWire
SAN DIEGO--(BUSINESS WIRE)--October 01, 2020--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharma executive with more than 25 years of experience in global clinical development and regulatory affairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005364/en/
Dr. Elizabeth Garofalo (Photo: Business Wire)
"Dr. Garofalo is a highly-regarded business leader and innovator with invaluable clinical development experience," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "We are excited to welcome her to the Board of Directors and look forward to leveraging her significant CNS research and development expertise, particularly as the company advances its innovative late stage and growing early stage pipeline."
"I look forward to working with the talented Acadia management team as they continue to seek breakthroughs in the field of CNS, pioneering new research and developing innovative new therapies to address unmet needs, " said Dr. Garofalo.
Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leadership roles including as the Global Head of Clinical Development and member of the Novartis Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board, Co-Head of the Novartis Neuroscience Franchise, Head of the Neuroscience Therapy Area at Astellas, Ann Arbor Site Head of Worldwide Regulatory Affairs at Pfizer, and Ann Arbor Site Head of Neuroscience at Pfizer.
Dr. Garofalo currently serves on the board for the Institute for Advanced Clinical Trials in Children and is the Chair of the Business Advisory Board for the Epilepsy Foundation of America. She earned her M.D. from the Indiana University School of Medicine and completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005364/en/
CONTACT: Media Contact:
Acadia Pharmaceuticals Inc.
Eric Endicott
(858) 914-7161
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com
SOURCE: Acadia Pharmaceuticals Inc.
Copyright Business Wire 2020
> Dow Jones Newswires
October 01, 2020 09:00 ET (13:00 GMT)
Recent ACAD News
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 05/09/2024 08:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:16 PM
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview • Business Wire • 05/08/2024 08:05:00 PM
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship • Business Wire • 04/29/2024 08:16:00 PM
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024 • Business Wire • 04/24/2024 08:05:00 PM
- Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada • Business Wire • 04/22/2024 01:04:00 PM
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada • Business Wire • 04/22/2024 01:04:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/19/2024 08:05:00 PM
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting • Business Wire • 04/17/2024 08:05:00 PM
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development • Business Wire • 04/02/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/01/2024 08:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/15/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day • Business Wire • 03/13/2024 08:05:00 PM
- Oracle Soars 13% With Exceptional Growth and Boosts Nvidia Shares With Collaboration Announcement, and More • IH Market News • 03/12/2024 11:21:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:05:55 PM
- Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia • Business Wire • 03/11/2024 08:05:00 PM
- Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024 • Business Wire • 02/29/2024 02:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:13:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:07:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:02:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:16:24 PM
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview • Business Wire • 02/27/2024 09:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 02/21/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 12:08:13 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM